Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
CVS Health Corporation (CVS) delivers integrated healthcare solutions through its retail pharmacies, pharmacy benefits management (CVS Caremark), and Aetna insurance services. This page provides investors and stakeholders with timely access to official announcements, financial disclosures, and strategic developments shaping the company’s role in the evolving healthcare landscape.
Track breaking updates across CVS Health’s core operations, including earnings reports, regulatory filings, partnership announcements, and service expansions. Our curated news collection simplifies monitoring of material events affecting pharmacy networks, insurance offerings, and digital health initiatives while maintaining compliance with financial disclosure standards.
Discover updates on prescription drug pricing strategies, MinuteClinic expansions, formulary changes through Caremark, and Medicare Advantage plan developments. The repository also covers leadership appointments, sustainability efforts, and community health programs central to CVS Health’s consumer-first mission.
Bookmark this page for streamlined access to CVS Health’s latest corporate communications. Combine these updates with SEC filings and earnings call transcripts available on Stock Titan for comprehensive investment analysis.
Biofourmis has achieved unicorn status following a $300 million Series D investment led by General Atlantic, with participation from CVS Health and other investors. The funds will enhance Biofourmis' virtual care solutions, including personalized in-home care, and expand clinical trials for digital therapies. Former Medtronic CEO, Dr. Omar Ishrak, has been appointed Chairman of the Board. The company aims to strengthen its presence in the value-based care market, focusing on improving patient outcomes while reducing costs.
CVS Health (NYSE: CVS) will hold a conference call on May 4, 2022, at 8:00 a.m. ET to discuss its first quarter 2022 financial results. The call will be accessible via an audio webcast on the CVS Health Investor Relations website, where the recording will be archived for a year. CVS Health is a leading health solutions provider, employing approximately 300,000 colleagues, including more than 40,000 physicians and pharmacists. The company focuses on improving health access, lowering costs, and enhancing patient care.
CVS Health announced its 2021 Environmental, Social and Governance (ESG) report, titled Healthy 2030, outlining initiatives for health equity and sustainability. Key achievements include:
- Health Zones initiative addressing social determinants of health
- Over 1,700 free health screenings for underserved communities
- 50% of waste diverted from landfills
- 33,500 MWh energy savings
- Minimum wage increased to $15/hour from July 2022
This marks the 15th annual report following various global sustainability standards.
CVS Health announced a $484 million settlement with the State of Florida to resolve opioid-related claims. The payment will be made over 18 years, allowing CVS to exit ongoing opioid lawsuits in Florida. CVS aims to refocus on enhancing healthcare services while the settlement funds will aid Florida's efforts against opioid abuse. The agreement includes no admission of wrongdoing, indicating that CVS will continue to defend against other opioid-related litigation. CVS emphasizes its existing initiatives to combat opioid misuse and support community health.
CVS Health, in partnership with Fresno Housing, is investing approximately $18.4 million to develop affordable housing in Fresno, California, through the Arthur @ Blackstone project. This initiative aims to support vulnerable groups such as transition age youth facing homelessness. The project will feature 41 housing units and offer comprehensive case management services. This investment is part of CVS's larger commitment to health equity, having invested $185 million in affordable housing nationwide in 2021 and a total of $1.3 billion over the last two decades.
OmniLife, a health technology platform for transplant hospitals, is a finalist for the 2022 Innovation Challenge by Lyfebulb and CVS Kidney Care. The challenge, aimed at improving kidney health, will award $25,000 to the best concept on May 19, 2022. OmniLife, committed to enhancing patient care in the transplant ecosystem, is also involved in NIH-funded clinical trials with major centers. The finalists will present scalable solutions to make kidney care more equitable and accessible, reflecting advancements needed in chronic kidney disease treatment.
Lyfebulb and CVS Kidney Care announced the 10 finalists for the 2022 Innovation Challenge aimed at enhancing health equity and outcomes in kidney disease. The challenge seeks innovative solutions to modernize treatment options for chronic kidney disease, which have largely remained stagnant. The finalists will present their ideas at a summit on May 18-19, 2022, in Austin, Texas, with the chance to win a $25,000 prize to support their initiatives. This initiative reflects CVS's commitment to addressing disparities in kidney health.
CVS Health Corporation (NYSE: CVS) announced the retirement of David W. Dorman as Independent Chair of the Board of Directors, effective May 11, 2022. Roger N. Farah has been selected to succeed him. Dorman has served since 2011 and joined the Board in 2006, while Tony L. White will also retire after being a director since 2011. CEO Karen S. Lynch praised Dorman's leadership and contributions to the company's growth. The Board will be reduced to 11 members following these retirements, as CVS Health continues to navigate the evolving healthcare landscape.
CVS Health has approved a quarterly dividend of $0.55 per share on March 9, 2022, for its common stock. This dividend will be payable on May 2, 2022, to shareholders on record as of April 22, 2022. As a leading health solutions provider, CVS Health aims to enhance community health through comprehensive services that include chronic disease management and affordable healthcare access.